Bacher, Ulrike

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Voigtlaender, Minna"],["dc.contributor.author","Vogler, Birthe"],["dc.contributor.author","Trepel, Martin"],["dc.contributor.author","Panse, Jens"],["dc.contributor.author","Jung, R."],["dc.contributor.author","Bokemeyer, Carsten"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Binder, M."],["dc.date.accessioned","2018-11-07T09:50:40Z"],["dc.date.available","2018-11-07T09:50:40Z"],["dc.date.issued","2015"],["dc.format.extent","238"],["dc.identifier.isi","000364268800571"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35752"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Hospital population screening reveals overrepresentation of CD5-monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","5512"],["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Krekeler, Carolin"],["dc.contributor.author","Reitnauer, Lea"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Khandanpour, Cyrus"],["dc.contributor.author","Steger, Leander"],["dc.contributor.author","Boeckel, Göran Ramin"],["dc.contributor.author","Klosner, Justine"],["dc.contributor.author","Tepasse, Phil-Robin"],["dc.contributor.author","Kemper, Marcel"],["dc.contributor.author","Hennies, Marc Tim"],["dc.contributor.author","Shumilov, Evgenii"],["dc.date.accessioned","2022-12-01T08:31:37Z"],["dc.date.available","2022-12-01T08:31:37Z"],["dc.date.issued","2022"],["dc.description.abstract","Background: Two-dose COVID-19 vaccination often results in poor humoral response rates in patients with hematologic malignancies (HMs); yet responses to COVID-19 booster vaccines and the risk of COVID-19 infection post-booster are mostly uncertain. Methods: We included 200 outpatients with HMs and predominantly lymphoid neoplasms (96%, 191/200) in our academic center and reported on the humoral responses, which were assessed by measurement of anti-spike IgG antibodies in peripheral blood as early as 14 days after mRNA-based prime-boost vaccination, as well as factors hampering booster efficacy. Previous basic (double) immunization was applied according to the local recommendations with mRNA- and/or vector-based vaccines. We also report on post-booster COVID-19 breakthrough infections that emerged in the Omicron era and the prophylaxis strategies that were applied to poor and non-responders to booster vaccines. Results: A total of 55% (110/200) of the patients achieved seroconversion (i.e., anti-spike protein IgG antibody titer > 100 AU/mL assessed in median 48 days after prime-boost vaccination) after prime-boost vaccination. Multivariable analyses revealed age, lymphocytopenia, ongoing treatment and prior anti-CD20 B-cell depletion to be independent predictors for booster failure. With each month between anti-CD20-mediated B-cell depletion and booster vaccination, the probability of seroconversion increased by approximately 4% (p < 0.001) and serum–antibody titer (S-AbT) levels increased by 90 AU/mL (p = 0.011). Notably, obinutuzumab treatment was associated with an 85% lower probability for seroconversion after prime-boost vaccination compared to rituximab (p = 0.002). Of poor or non-responders to prime-boost vaccination, 41% (47/114) underwent a second booster and 73% (83/114) underwent passive immunization. COVID-19 breakthrough infections were observed in 15% (29/200) of patients after prime-boost vaccination with predominantly mild courses (93%). Next to seroconversion, passive immunization was associated with a significantly lower risk of COVID-19 breakthrough infections after booster, even in vaccine non-responders (all p < 0.05). In a small proportion of analyzed patients with myeloid neoplasms (9/200), the seroconversion rate was higher compared to those with lymphoid ones (78% vs. 54%, accordingly), while the incidence rate of COVID-19 breakthrough infections was similar (22% vs. 14%, respectively). Following the low frequency of myeloid neoplasms in this study, the results may not be automatically applied to a larger cohort. Conclusions: Patients with HMs are at a high risk of COVID-19 booster vaccine failure; yet COVID-19 breakthrough infections after prime-boost vaccination are predominantly mild. Booster failure can likely be overcome by passive immunization, thereby providing immune protection against COVID-19 and attenuating the severity of COVID-19 courses. Further sophistication of clinical algorithms for preventing post-vaccination COVID-19 breakthrough infections is urgently needed."],["dc.identifier.doi","10.3390/cancers14225512"],["dc.identifier.pii","cancers14225512"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118221"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","2072-6694"],["dc.title","Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Ganster, Christina"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Dierks, Sascha"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Stuhlmann, Reingard"],["dc.contributor.author","Baesecke, Joerg"],["dc.contributor.author","Sievers, B."],["dc.contributor.author","Simon-Becker, S."],["dc.contributor.author","Flach, J."],["dc.contributor.author","Martin, R."],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T10:13:03Z"],["dc.date.available","2018-11-07T10:13:03Z"],["dc.date.issued","2016"],["dc.format.extent","495"],["dc.identifier.isi","000379484601582"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40359"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ferrata Storti Foundation"],["dc.publisher.place","Pavia"],["dc.relation.conference","21st Congress of the European-Hematology-Association"],["dc.relation.eventlocation","Copenhagen, DENMARK"],["dc.relation.issn","0390-6078"],["dc.title","SPATIAL INTERACTION OF CYTOGENETIC AND MOLECULAR MUTATIONS IN MYELODYSPLASTIC SYNDROMES"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2476"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Leukemia & Lymphoma"],["dc.bibliographiccitation.lastpage","2480"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Hellige, Niels"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Binder, Mascha"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T18:43:56Z"],["dc.date.available","2020-12-10T18:43:56Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.3109/10428194.2016.1151510"],["dc.identifier.eissn","1029-2403"],["dc.identifier.issn","1042-8194"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78273"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","58"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","66"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Klyuchnikov, Evgeny"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Hung, Rayjean J."],["dc.contributor.author","Carreras, J."],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Hari, Parameswaran N."],["dc.contributor.author","Ku, G. H."],["dc.contributor.author","Ayala, E."],["dc.contributor.author","Chen, A. L."],["dc.contributor.author","Chen, Y-B"],["dc.contributor.author","Cohen, Jonathon B."],["dc.contributor.author","Freytes, Cesar O."],["dc.contributor.author","Gale, Robert Peter"],["dc.contributor.author","Kamble, Rammurti"],["dc.contributor.author","Kharfan-Dabaja, Mohamed A."],["dc.contributor.author","Lazarus, Hillard M."],["dc.contributor.author","Martino, Roberto D."],["dc.contributor.author","Mussetti, Alberto"],["dc.contributor.author","Savani, Bipin N."],["dc.contributor.author","Schouten, H. C."],["dc.contributor.author","Usmani, Saad Z."],["dc.contributor.author","Wiernik, Peter H."],["dc.contributor.author","Wirk, Baldeep Mona"],["dc.contributor.author","Smith, Sonali M."],["dc.contributor.author","Sureda, Anna M."],["dc.contributor.author","Hamadani, Mehdi"],["dc.date.accessioned","2018-11-07T10:21:17Z"],["dc.date.available","2018-11-07T10:21:17Z"],["dc.date.issued","2016"],["dc.description.abstract","Grade 3 follicular lymphoma (FL) has aggressive clinical behavior. To evaluate the optimal first transplantation approach in relapsed/refractory grade 3 FL patients, we compared the long-term outcomes after allogeneic (allo-) vs autologous hematopoietic cell transplantation (auto-HCT) in the rituximab era. A total of 197 patients undergoing first reduced-intensity conditioning (RIC) allo-HCT or first auto-HCT during 2000-2012 were included. Rituximab-naive patients were excluded. Allo-HCT recipients were younger, more heavily pretreated and had a longer interval between diagnosis and HCT. The 5-year probabilities of non-relapse mortality (NRM), relapse/progression, PFS and overall survival (OS) for auto-HCT vs allo-HCT groups were 4% vs 27% (P < 0.001), 61% vs 20% (P < 0.001), 36% vs 51% (P=0.07) and 59% vs 54% (P=0.7), respectively. On multivariate analysis, auto-HCT was associated with reduced risk of NRM (relative risk (RR) = 0.20; P=0.001). Within the first 11 months post HCT, auto- and allo-HCT had similar risks of relapse/progression and PFS. Beyond 11 months, auto-HCT was associated with higher risk of relapse/progression (RR=21.3; P=0.003) and inferior PFS (RR = 3.2; P=0.005). In the first 24 months post HCT, auto-HCT was associated with improved OS (RR = 0.42; P=0.005), but in long-time survivors (beyond 24 months) it was associated with inferior OS (RR=3.6; P=0.04). RIC allo-HCT as the first transplant approach can provide improved PFS and OS, in long-term survivors."],["dc.identifier.doi","10.1038/bmt.2015.223"],["dc.identifier.isi","000368469800009"],["dc.identifier.pmid","26437062"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42057"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1476-5365"],["dc.relation.issn","0268-3369"],["dc.title","Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Germing, U."],["dc.contributor.author","Schuler, E."],["dc.contributor.author","Schulz, Xenia"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Nolte, F."],["dc.contributor.author","Hofmann, W-K"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Goetze, K."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Letsch, Anne"],["dc.contributor.author","Schafhausen, Philippe"],["dc.contributor.author","Bug, G."],["dc.contributor.author","Bruemmendorf, Tim Hendrik"],["dc.contributor.author","Haas, Rainer"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Haase, Detlef"],["dc.date.accessioned","2018-11-07T10:07:38Z"],["dc.date.available","2018-11-07T10:07:38Z"],["dc.date.issued","2016"],["dc.format.extent","235"],["dc.identifier.isi","000385691300581"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39317"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Cytogenetic monitoring from peripheral blood in patients with myelodysplastic syndrome: First results from the German LEMON-5 trial"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","110"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Holler, Ernst"],["dc.contributor.author","Kobbe, Guido"],["dc.contributor.author","Bornhaeuser, Martin"],["dc.contributor.author","Schwerdtfeger, Rainer"],["dc.contributor.author","Nagler, Amon"],["dc.contributor.author","Bethge, Wolfgang A."],["dc.contributor.author","Stelljes, Matthias"],["dc.contributor.author","Uharek, Luiz"],["dc.contributor.author","Wandt, Hannes"],["dc.contributor.author","van Os, Marleen"],["dc.contributor.author","Burchert, Andreas"],["dc.contributor.author","Corradini, Paolo"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Kaufmann, Martin"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Einsele, Hermann"],["dc.contributor.author","Gramatzki, Martin"],["dc.contributor.author","Zabelina, Tatjana"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Zander, Axel R."],["dc.contributor.author","Heinzelmann, Marion"],["dc.contributor.author","Kvasnicka, Michael"],["dc.contributor.author","Thiele, Juergen"],["dc.contributor.author","Niederwieser, Dietger"],["dc.contributor.author","de Witte, Theo M."],["dc.date.accessioned","2018-11-07T10:52:20Z"],["dc.date.available","2018-11-07T10:52:20Z"],["dc.date.issued","2007"],["dc.format.extent","210A"],["dc.identifier.isi","000251100800684"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49090"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","49th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","Atlanta, GA"],["dc.relation.issn","0006-4971"],["dc.title","Dose-reduced conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Results from a Multicenter prospective trial of the chronic leukemia working party of the European group for blood and marrow transplantation (EBMT)."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Mueller-Thomas, Catharina"],["dc.contributor.author","Goetze, K."],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Germing, U."],["dc.contributor.author","Hofmann, W.-K."],["dc.contributor.author","Giagounides, A. A. N."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Sole, Francesco"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Tuechler, Heinz"],["dc.contributor.author","Pfeilstoecker, Michael"],["dc.contributor.author","Hildebrandt, B."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schanz, J."],["dc.date.accessioned","2018-11-07T09:50:35Z"],["dc.date.available","2018-11-07T09:50:35Z"],["dc.date.issued","2015"],["dc.format.extent","33"],["dc.identifier.isi","000364268800070"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35737"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Underestimation of 12p-deletion in myelodysplastic syndromes? Results from a German diagnostic study in comparison with an international control group"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3202"],["dc.bibliographiccitation.issue","25"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","3214"],["dc.bibliographiccitation.volume","127"],["dc.contributor.author","Schieferdecker, Aneta"],["dc.contributor.author","Oberle, Anna"],["dc.contributor.author","Thiele, Benjamin"],["dc.contributor.author","Hofmann, Fabian"],["dc.contributor.author","Goethel, Markus"],["dc.contributor.author","Miethe, Sebastian"],["dc.contributor.author","Hust, Michael"],["dc.contributor.author","Braig, Friederike"],["dc.contributor.author","Voigt, Mareike"],["dc.contributor.author","von Pein, Ute-Marie"],["dc.contributor.author","Koch-Nolte, Friedrich"],["dc.contributor.author","Haag, Friedrich"],["dc.contributor.author","Alawi, Malik"],["dc.contributor.author","Indenbirken, Daniela"],["dc.contributor.author","Grundhoff, Adam"],["dc.contributor.author","Bokemeyer, Carsten"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Kroeger, Nicolaus M."],["dc.contributor.author","Binder, Mascha"],["dc.date.accessioned","2018-11-07T10:12:39Z"],["dc.date.available","2018-11-07T10:12:39Z"],["dc.date.issued","2016"],["dc.description.abstract","Multiplemyeloma(MM) is a hematological cancer for which immune-based treatments are currently in development. Many of these rely on the identification of highly disease specific, strongly and stably expressed antigens. Here, we profiled the myeloma B-cell immunome both to explore its predictive role in the context of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and to identify novel immunotherapeutic targets. We used random peptide phage display, reverse immunization, and next-generation sequencing-assisted antibody phage display to establish a highly myeloma-specific epitope fingerprint targeted by B-cell responses of 18 patients in clinical remission. We found that allogeneic HSCT more efficiently allowed production of myeloma-specific antibodies compared with autologous HSCT and that a highly reactive epitope recognition signature correlated with superior response to treatment. Next, we performed myeloma cell surface screenings of phage-displayed patient transplant immunomes. Although some of the screenings yielded clear-cut surface binders, the majority of screenings did not, suggesting that many of the targeted antigens may in fact not be accessible to the B-cell immune system in untreated myeloma cells. This fit well with the identification of heat-shock proteins as a class of antigens that showed overall the broadest reactivity with myeloma patient sera after allogeneic HSCT and that may be significantly translocated to the cell surface upon treatment as a result of immunogenic cell death. Our data reveal a disease-specific epitope signature of MM that is predictive for response to treatment. Mining of transplant immunomes for strong myeloma surface binders may open up avenues for myeloma immunotherapy."],["dc.description.sponsorship","Hubertus Wald-Foundation, Hamburg; [110906]"],["dc.identifier.doi","10.1182/blood-2015-10-676536"],["dc.identifier.isi","000378337700014"],["dc.identifier.pmid","27034429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40279"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","1528-0020"],["dc.relation.issn","0006-4971"],["dc.title","A transplant \"immunome\" screening platform defines a targetable epitope fingerprint of multiple myeloma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","64"],["dc.bibliographiccitation.journal","Critical Reviews in Oncology/Hematology"],["dc.bibliographiccitation.lastpage","79"],["dc.bibliographiccitation.volume","126"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Flach, Johanna"],["dc.contributor.author","Pabst, Thomas"],["dc.contributor.author","Fiedler, Martin"],["dc.contributor.author","Angelillo-Scherrer, Anne"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Joncourt, Raphael"],["dc.contributor.author","Kohlmann, Alexander"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T14:23:20Z"],["dc.date.available","2020-12-10T14:23:20Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.critrevonc.2018.03.020"],["dc.identifier.issn","1040-8428"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71901"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]